Background
Frasier syndrome is a rare genetic nephropathy caused by a point mutation in the WT 1 gene located on chromosome 11.14 First described in 1964 by Professor Frasier,5 it is characterized by the presence of progressive glomerulopathy with proteinuria associated with male pseudo hermaphroditism (presence of female external genitalia in a male phenotype).2,3,68 Initial manifestations of patients with Frasier syndrome include morning edema (facial puffiness), elevated blood pressure, proteinuria, with hypospadias and/or ambiguity of the external genitalia accompanied by cryptorchidism at birth.2,3,9 The symptomatology evolves into a treatment-resistant nephrotic syndrome that progressively leads to end-stage renal failure during the first two decades of the childs life.2,3,6,911 We present a case of Frasier syndrome that was seen at the nephrology/dialysis unit of HUEH.
This is a young phenotypically male (presence of secondary male characteristics) who is 19 years old and born with a genital malformation in a family without history of consanguinity. They were seen on referral at the nephrology/dialysis unit of the internal medicine department of HUEH for evaluation and follow-up. Insidious progression of symptoms had occurred over 3 years. However, the patient developed new symptoms over the 21 days preceding this consultation at the hospital. The patient was experiencing morning puffiness of the face and postprandial vomiting. He had episodes of dyspnea with effort that evolved into dyspnea at rest, orthopnea requiring two pillows, and paroxysmal nocturnal dyspnea. He also developed ascending edema of the lower limbs with malleolar onset. At an outside hospital, urine examination showed proteinuria (+++), urinary tract infection with severe leukocyturia (3035 white blood cells per field) and hematuria (68 red blood cells per field). He had a severe anemia (7.8 g/dl), normocytic normochromic (MCV: 84.1; MCHC: 34.2), a predominantly neutrophilic hyperleukocytosis (14,000; 86%), an altered ionogram with mild hyperkalemia (5.71 mEq/L) and an altered renal balance with creatininemia (25.25 mg/dl); BUN (90 mg/dl). In the light of these assessments, he was referred to the emergency department and followed up with nephrology for appropriate care.
In the emergency room, he was noted to have a puffy face, pale palpebral conjunctiva, and crackling rales at the base of the left lung. His scrotum was empty to palpation and enlarged, though nontender. His external genitalia were characterized by a micropenis with the presence of a rough vaginal orifice attached to the perineum.
Over three months of outpatient follow-up, he had four sets of renal labs drawn, and all showed impaired renal function (Figure 1). The last one revealed a creatinine level of 10.5 mg/dl. The glomerular filtration rate was calculated: MDRD eGFR = 8.21 mL/min/1.73. His phosphocalcic assessment showed hypocalcemia at 8.1 mg/dl and a 24-hour proteinuria at 578 mg. During the same period, he had four altered blood counts showing severe anemia that did not correct (Figure 1), and the last of these revealed a severe microcytic hypochromic anemia with a hemoglobin level of 7.4 gr/dl, MCV at 79.2 fl. and a MCHC at 26.6 pg, and hyperleukocytosis of 15,800 with neutrophilic predominance (76%). His hormonal tests showed a decrease in testosterone level to 242 ng/dl, an increase in hydroxyprogesterone level to 67.9, and an increased LH level to 26 mlU/mL.
Figure 1 Variation of hemoglobin and creatininemia over the last 3 months.
He also had an abdominal pelvic ultrasound showing poor cortico-medullary differentiation with small kidneys (right kidney 9.7*5.02 cm; left kidney 9.7*5.6 cm) and dilatation of the pyelocaliceal system and proximal ureter (Figure 2). Bilateral cryptorchidism is also described in the inguinal region (right testicles 2.7*1.1 cm and left 1.37*1.04 cm), and presence of functional ovaries (1.6*1.1 cm on the right and 1.5*1.7 cm on the left) with follicles of variable size scattered in the parenchyma (Figure 3). He also has a prostate gland (4.83cm3). Doppler ultrasound of the kidneys described a significant alteration of the renal vascularization and an absence of opacification of the cortical arteries in the periphery. He had performed an echocardiogram concluding a dilated cardiomyopathy with mild alteration of the systolic ejection fraction (46.4%) associated with a pericardial effusion without signs of tamponade. Chest radiography also described congestive cardiomegaly with signs of vessel cephalization and impaction of the left hilum.
Figure 2 Ultrasound of the kidneys (L: left; R: right).
Figure 3 Identification of the testicles (in the inguinal region), ovaries and the empty srotum on abdominal-pelvic ultrasound.
In the light of these anamnestic, clinical and paraclinical findings, we concluded to the diagnosis of end-stage renal failure by progressive glomerulopathy in a context of Frasiers syndrome complicated by a global cardiac decompensation class IV.
During his stay on the unit, he received 31 sessions of hemodialysis and 9-unit bags of compatible packed red blood cells that did little to correct his anemia (Figure 1). He was managed for cardiac decompensation and was placed on furosemide, enalapril, carvedilol, iron, thiamine, erythropoietin and omeprazole. After 12 days, he developed a compensated heart disease and his clinical condition improved, so he was discharged. He continued hemodialysis sessions in the unit and genetic tests were planned to investigate possible mutations that would be diagnostic of Frasier syndrome. However, he suddenly succumbed to cardiac arrest in post-dialysis.
Mutations in the WT1 gene result in a spectrum of very rare congenital diseases characterized by abnormalities in gonadal and urinary tract development and are the cause of WAGR (Wilms-Aniridia-Genitourinary-mental Retardation) syndromes, Denys-Drash syndrome and Frasier syndrome.3,7,12,13 Initial manifestations of patients with nephropathy due to the WT1 gene mutation include edema, proteinuria, pseudo hermaphroditism, hypospadias or cryptorchidism at birth.9 Frasier syndrome and Denys-Drash syndrome (DDS) share common features and are both characterized by a steroid-resistant nephrotic syndrome, which leads to renal failure, gonadal tumor (most often gonadoblastoma or dysgerminoma), and male pseudo hermaphroditism.2,12,14 The main differences lie in the more prominent manifestation of renal symptomatology during childhood in DDS, contrasting FS which mostly manifests during the second decade, particularly during adolescence or young adulthood.3,7,9,12,15,16 Additionally, the risk of development Wilms tumors is higher in DDS.3,6,7,12,13,16,17 In our case, we eliminated DDS because the renal failure occurs mainly in the second decade (1619 years), as mentioned in the literature.6,7,18,19
Frasier syndrome is defined by the presence of progressive glomerulopathy with proteinuria associated with male pseudo hermaphroditism (presence of female external genitalia in a male phenotype).2,3,68 To our knowledge, this case is the first described in Haiti. Taking into account the appearance of the external genitalia, phenotype and sex chromosomes, Frasier syndrome is classified into 3 types:2
This case was closest to type 2 because of the male phenotype with predominant development of male sexual characteristics (no well-defined breasts or vagina). The mean age at diagnosis of Frasier syndrome was estimated to be 16.32.3 years,2,15,20 which is also the age at which the diagnosis of end-stage renal disease is often made, although the onset of renal symptoms of proteinuria, edema and hypertension typically begins between 2 and 10 years of age.1,2,6,9,10,19,20 This patient had a similar picture; since his childhood he was often in hospital for reasons of facial oedema and alteration of the renal function. This prompted the abdominal ultrasound revealing a decrease in kidney size of kidneys, and allowed the diagnosis of preterminal renal insufficiency at age 16.
Two elements are essential to confirm the diagnosis of Frasier syndrome: renal biopsy and cytogenetic study that identifies the WT1 gene mutation located on chromosome 11p13.7 Renal biopsy performed before the stage of end-stage failure describes segmental and focal glomerulosclerosis8,18,21 generally caused by the WT1 gene mutation leading to alterations in the podocytes with areas of proliferation.8,9,15 It is due to point mutations in intron 9 of the WT1 gene, resulting in the loss of the lysine-threonine-serine (KTS) containing isoforms of the WT1 protein and result in deficiency of the usually more abundant KTS positive isoforms and reversal of the normal KTS positive/negative ratio from 2:1 to 1:2.16 This has a great impact on tumor risk, because patients with Frasier syndrome have one normal copy of WT1 and one that can only produce the KTS negative isoform, this might explain why patients with Frasier syndrome do not develop Wilmss tumor which also explains the observed external genitalia changes, because the KTS positive isoform might participate in another pathway required for normal male urogenital development.2,16,19 There are extrarenal manifestations of the WT1 gene mutation such as the presence of cardiomyopathies,21 a finding that was identified in our patient at echocardiography showing dilated cardiomyopathy with slight alteration of the systolic ejection fraction (46, 4%). However, this could also be a complication of his chronic end-stage renal failure.
In our case, the renal biopsy was no longer appropriate since he had arrived at the nephrology unit very late and already had end-stage renal failure with hypotrophic kidneys. During his stay, we conducted genetic tests to confirm the presence of the mutations. Unfortunately, he died suddenly due to cardiac arrest after a dialysis session. As a result, the genetic tests were not performed to confirm mutations that would explain the clinical and paraclinical findings characteristic of Frasier syndrome.
With any clinical picture consisting of genital anomalies at birth, renal symptomatology (facial edema, proteinuria and high blood pressure) during childhood and the diagnosis of renal failure during adolescence, rare genetic nephropathies, such as Frasier syndrome and Denys Drash syndrome, must be considered.7,12,20,23 In low-income settings such as ours, where genetic technology is not always available, the diagnosis of Frasier syndrome should be considered in any child with developmental abnormalities of the external genitalia presenting with isolated proteinuria and/or signs of impaired renal function during childhood or adolescence.
This study has been approved for publication by the head directory of the Internal Medicine of the State University Hospital of Haiti as it is a teaching hospital.
The patients mother consented to participate and publish the relevant information about the case, and the information about the identity was kept confidential.
Special thanks to Dr. Nelle-Ange Mele, Dr. Joseph Daniel Perez de Corcho, and Dr. Rolvix Patterson, for their invaluable help in translating the manuscript.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
The authors report no conflicts of interest for this work.
1. Yang Y, Zhao F, Tu X, Yu Z. Mutations in WT1 in boys with sporadic isolated steroid-resistant nephrotic syndrome. Genet Mol Res. 2016;15(1):15017559. doi:10.4238/gmr.15017559
2. Ezaki J, Hashimoto K, Asano T, et al. Gonadal tumor in Frasier syndrome: a review and classification. Cancer Prev Res. 2015;8(4):271276. doi:10.1158/1940-6207.CAPR-14-0415
3. Peco-Anti A, Ozaltin F, Parezanovi V, Miloevski-Lomi G, Zdravkovi V. Proteinuria in Frasier syndrome. Srp Arh Celok Lek. 2013;141(910):685688. doi:10.2298/SARH1310685P
4. Hildebrandt F. Genetic kidney diseases. Lancet. 2010;375(9722):12871295. doi:10.1016/S0140-6736(10)60236-X
5. Frasier SD, Bashore RA, Mosier HD. Gonadoblastoma associated with pure gonadal dysgenesis in monozygous twins. J Pediatr. 1964;64(5):740745. doi:10.1016/S0022-3476(64)80622-3
6. Jalanko H, Kriinen H. Nephrotic Disorders. 6th ed. Elsevier; 2013. doi:10.1016/B978-0-12-383834-6.00068-9
7. Miller-Hodges E. Clinical aspects of WT1 and the kidney. Methods Mol Biol. 2016;1467:1521. doi:10.1007/978-1-4939-4023-3_2
8. Demmer L, Primack W, Loik V, Brown R, Therville N, Mcelreavey K. Frasier Syndrome. J Am Soc Nephrol. 1999;10(10):22152218. doi:10.1681/ASN.V10102215
9. Sun S, Xu L, Bi Y, et al. Early diagnosis of WT1 nephropathy and follow up in a Chinese multicenter cohort. Eur J Med Genet. 2020;63(11):104047. doi:10.1016/j.ejmg.2020.104047
10. Ruf RG, Schultheiss M, Lichtenberger A, Karle SM. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int. 2004;66(2):564570. doi:10.1111/j.1523-1755.2004.00775.x
11. Melo KFS, Martin RM, Costa EMF, et al. An unusual phenotype of Frasier syndrome due to IVS9 +4C>T mutation in the WT1 gene: predominantly male ambiguous genitalia and absence of gonadal dysgenesis. J Clin Endocrinol Metab. 2002;87(6):25002505. doi:10.1210/jcem.87.6.8521
12. Liu EK, Suson KD. Syndromic Wilms tumor: a review of predisposing conditions, surveillance and treatment. Transl Androl Urol. 2020;9(5):23702381. doi:10.21037/tau.2020.03.27
13. Yang YH, Zhao F, Feng DN, et al. Wilms tumor suppressor gene mutations in girls with sporadic isolated steroid-resistant nephrotic syndrome. Genet Mol Res. 2013;12(4):61846191. doi:10.4238/2013.December.4.5
14. Avni EF, Vandenhoute K, Devriendt A, et al. Update on congenital nephrotic syndromes and the contribution of US. Pediatr Radiol. 2011;41(1):7681. doi:10.1007/s00247-010-1793-5
15. Chiba Y, Inoue CN. Once-daily low-dose cyclosporine a treatment with angiotensin blockade for long-term remission of nephropathy in Frasier syndrome. Tohoku J Exp Med. 2019;247(1):3540. doi:10.1620/tjem.247.35
16. Koziell A, Grundy R. Frasier and Denys-Drash syndromes: different disorders or part of a spectrum? Arch Dis Child. 1999;81:365369. doi:10.1136/adc.81.4.365
17. Tasic V, Gucev Z, Polenakovic M. Steroid resistant nephrotic syndrome-genetic consideration. Pril. 2015;36(3):512. doi:10.1515/prilozi-2015-0073
18. Hashimoto H, Zhang X, Zheng Y, Wilson GG, Cheng X. Denys-Drash syndrome associated WT1 glutamine 369 mutants have altered sequence-preferences and altered responses to epigenetic modifications. Nucleic Acids Res. 2016;44(21):1016510176. doi:10.1093/nar/gkw766
19. Matsuoka D, Noda S, Kamiya M, et al. Immune-complex glomerulonephritis with a membranoproliferative pattern in Frasier syndrome: a case report and review of the literature. BMC Nephrol. 2020;21(1). doi:10.1186/s12882-020-02007-0
20. Lipsk BS, Lipsk BS, Ranchin B, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney Int. 2014;85(5):11691178. doi:10.1038/ki.2013.519
21. Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the podoNet registry cohort. Clin J Am Soc Nephrol. 2015;10(4):592600. doi:10.2215/CJN.06260614
22. Park E, Lee C, Kim NKD, et al. Genetic study in Korean pediatric patients with steroid-resistant nephrotic syndrome or focal segmental glomerulosclerosis. J Clin Med. 2020;9(6):2013. doi:10.3390/jcm9062013
23. Chan AOK, But WM, Lee CY, et al. Aetiological bases of 46, XY disorders of sex development in the Hong Kong Chinese population. Hong Kong Med J. 2015;21(6):499510. doi:10.12809/hkmj144402
Original post:
Suspicion of Frasier's syndrome in the nephrology unit | IMCRJ - Dove Medical Press
- Cardiomyopathy what it is and types British Heart Foundation [Last Updated On: April 12th, 2018] [Originally Added On: April 12th, 2018]
- Cardiomyopathy what it is and types British Heart ... [Last Updated On: May 28th, 2018] [Originally Added On: May 28th, 2018]
- Cardiomyopathy - what it is and types - British Heart ... [Last Updated On: June 6th, 2018] [Originally Added On: June 6th, 2018]
- Cardiomyopathy Symptoms, Types, Treatment & Prognosis [Last Updated On: November 5th, 2018] [Originally Added On: November 5th, 2018]
- Mark Drazner, M.D.: Internal Medicine | Cardiomyopathies ... [Last Updated On: December 20th, 2018] [Originally Added On: December 20th, 2018]
- Overview of Cardiomyopathies - Cardiovascular Disorders ... [Last Updated On: December 27th, 2018] [Originally Added On: December 27th, 2018]
- Cardiomyopathy | Cleveland Clinic [Last Updated On: April 24th, 2019] [Originally Added On: April 24th, 2019]
- Cardiomyopathy | pathology | Britannica.com [Last Updated On: April 29th, 2019] [Originally Added On: April 29th, 2019]
- Cardiomyopathy | Children's Hospital of Philadelphia [Last Updated On: April 29th, 2019] [Originally Added On: April 29th, 2019]
- Cardiac Surgery Instruments Market Prospects and Growth Assessment - TodayTimes [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market to Record an Exponential CAGR by 2025 - Rapid News Network [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Cardiovascular Genomic Diagnostics Market Estimated to Expand at a Robust CAGR over 2018 2028 - Space Market Research [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting - Yahoo Finance [Last Updated On: October 9th, 2019] [Originally Added On: October 9th, 2019]
- Cardiac Surgery Instruments Market to be Fueled by Increasing Threat of Cardiovascular Diseases - Online News Guru [Last Updated On: October 21st, 2019] [Originally Added On: October 21st, 2019]
- Cell Culture Protein Surface Coating Market Current Outlook Of Industry & Forecast 2017 2025 - Health News Office [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]
- Cytokinetics to Announce Third Quarter Results on October 31, 2019 - Yahoo Finance [Last Updated On: October 24th, 2019] [Originally Added On: October 24th, 2019]
- Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies - PRNewswire [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies - Pharmaceutical... [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- Cytokinetics Announces New Results Presented at the International Symposium on ALS/MNDSubgroup Analyses of FORTITUDE-ALS on Effects of Reldesemtiv... [Last Updated On: December 8th, 2019] [Originally Added On: December 8th, 2019]
- Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 - Filmi Baba [Last Updated On: January 4th, 2020] [Originally Added On: January 4th, 2020]
- New PET tracer provides insight on cardiac failure risk after heart attack - DOTmed HealthCare Business News [Last Updated On: January 12th, 2020] [Originally Added On: January 12th, 2020]
- PET tracer can help fight heart attacks earlier in the process - Health Imaging [Last Updated On: January 12th, 2020] [Originally Added On: January 12th, 2020]
- Atrial fibrillation in athletes - CMAJ [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure -... [Last Updated On: February 9th, 2020] [Originally Added On: February 9th, 2020]
- Cytokinetics to Announce Fourth Quarter Results on March 3, 2020 - Yahoo Finance [Last Updated On: February 25th, 2020] [Originally Added On: February 25th, 2020]
- Stealth BioTherapeutics to Present at 40th Annual Cowen Health Care Conference - PRNewswire [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- Cell Culture Protein Surface Coating Market Analysis On Trends & Need 2025 - 3rd Watch News [Last Updated On: March 18th, 2020] [Originally Added On: March 18th, 2020]
- Heart patients dont need to panic: Doc - The Tribune India [Last Updated On: March 18th, 2020] [Originally Added On: March 18th, 2020]
- Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020 - Yahoo Finance [Last Updated On: April 1st, 2020] [Originally Added On: April 1st, 2020]
- Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights - BioSpace [Last Updated On: April 1st, 2020] [Originally Added On: April 1st, 2020]
- Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 - Tewksbury town crier [Last Updated On: May 5th, 2020] [Originally Added On: May 5th, 2020]
- BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases - Endpoints News [Last Updated On: May 5th, 2020] [Originally Added On: May 5th, 2020]
- Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy - thepress.net [Last Updated On: May 12th, 2020] [Originally Added On: May 12th, 2020]
- Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September - Yahoo Finance [Last Updated On: September 12th, 2020] [Originally Added On: September 12th, 2020]
- What we know about what it's like to recover from Covid-19 and its long-term effects - Local News 8 - LocalNews8.com [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Should You Buy Myokardia Inc (MYOK) Stock After it Is Up 64.52% in a Week? - InvestorsObserver [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Heart Failure from ATTRwt Amyloid Cardiomyopathy is Associated with Poor Prognosis - DocWire News [Last Updated On: October 7th, 2020] [Originally Added On: October 7th, 2020]
- Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human R - PharmiWeb.com [Last Updated On: December 16th, 2020] [Originally Added On: December 16th, 2020]
- Counties combine push for more vaccines - The Record Newspapers - TheRecordLive.com [Last Updated On: January 26th, 2021] [Originally Added On: January 26th, 2021]
- Vet Speak: Cats are very good at hiding the signs of heart disease - RossShire Journal [Last Updated On: January 26th, 2021] [Originally Added On: January 26th, 2021]
- Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights - Yahoo Finance [Last Updated On: May 25th, 2021] [Originally Added On: May 25th, 2021]
- Delta has set back herd immunity estimates. Heres how that affects the course of the pandemic - The Dallas Morning News [Last Updated On: August 14th, 2021] [Originally Added On: August 14th, 2021]
- Hypertrophic Cardiomyopathy Market to be Driven by the Emergence of Novel Pharmacotherapies & Gene-directed Approaches at a 22.24% CAGR During the... [Last Updated On: August 14th, 2021] [Originally Added On: August 14th, 2021]
- Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights - PRNewswire [Last Updated On: November 18th, 2021] [Originally Added On: November 18th, 2021]
- Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference - GuruFocus.com [Last Updated On: November 18th, 2021] [Originally Added On: November 18th, 2021]
- What is cardiac transplantation? An overview - Emergency Live International [Last Updated On: October 6th, 2022] [Originally Added On: October 6th, 2022]
- Fixing Heart Failure Workforce Issues: Baby Steps Start This Year - Medpage Today [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- Inherited Cardiac Disease Genetic Diagnoses Linked to Ancestry ... - GenomeWeb [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- VIDEO: Using genetics in cardiology to enable earlier interventions - Cardiovascular Business [Last Updated On: January 10th, 2023] [Originally Added On: January 10th, 2023]
- Ahmad Masri, MD, MS: 2024 Update on Development and Future of Cardiac Myosin Inhibitor Class - MD Magazine [Last Updated On: February 20th, 2024] [Originally Added On: February 20th, 2024]